The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
QuANTUM-First: Efficacy analysis in newly diagnosed FLT3-ITD-positive AML
|
An exploratory analysis from QuANTUM-First (NCT02668653), a phase III study of quizartinib plus chemotherapy in patients with newly diagnosed FLT3-internal tandem duplication (ITD)-positive acute myeloid leukemia (AML) who received continuation therapy, was presented at the European Hematology Association 2024 Hybrid Congress by Mikkael Sekeres.1 |
| Key learnings1 |
| At a median follow-up of 39.2 months, median overall survival (OS) was not reached in either the quizartinib (n = 116) or placebo arms (n = 92) (hazard ratio [HR], 0.683; 95% confidence interval [CI], 0.395–1.183). However, at 48 months the OS rate was numerically higher for quizartinib (76.3%) vs placebo (67.9%). |
| From baseline to 36 months, a higher relapse-free survival (RFS) rate was observed in the quizartinib arm. However, in the long-term, median RFS was not reached in the placebo arm and was 48.6 months with quizartinib. |
| A higher proportion of patients (71%) in the quizartinib arm proceeded to continuation therapy after allogenic-hematopoietic stem cell transplant (allo-HSCT) vs placebo (55%). |
| In patients who did not receive allo-HSCT, there was an OS benefit in those treated with quizartinib, with a 60% reduction in the risk of death compared with placebo. |
| These findings support the use of quizartinib throughout the treatment regimen in patients with ND FLT3-mutated AML and suggest that implementation of measurable residual disease in future studies may help identify patients who will receive the most benefit from treatment with quizartinib. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
